US to trial Star Wars-like headgear to spot brain injuries in a snap on battlefields
The clinical trials are slated to begin in June 2025, they will aim to ascertain the capabilities of the device.
Related Articles
Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset
In-depth analysis of myeloid cells residing within the RA joint reveals a unique early signature associated with disease activity.
Knowledge workers are leaning on generative AI as their workloads mount
Americans are struggling at work, according to a new report from Wrike.
T-Mobile US achieves new record in 5G uplink speed via 5G DC
The 5G tests was completed using T-Mobile’s 5G SA production network in SoFi Stadium in Southern California.
Medpal Tulsa
MedPal Tulsa is free to use and lists cash-pay prices published by health care providers in the Tulsa area in compliance with state and federal…
Childhood Community Disadvantage and Structural Brain Integrity After Age 65 Years
This cohort study of US adults in a regional integrated health care network examines the association of childhood residence in an economically disadvantaged community, individual…
AI Algorithms Accurately Predict Antibiotic Resistance in UTI
AI algorithms accurately predict selection of antibiotics for UTI up to three days before culture results are available. #AUA2024
Opioid vs. Opiate: Is There a Difference?
What’s the difference between opiates and opioids? A psychiatrist and substance use disorder specialist explains how the two are more similar than different.
Lumateperone Prevents Relapse in Patients With Schizophrenia
Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.
More lung-cancer cases detected earlier
Specially adapted lorries have been visiting towns to offer NHS checks in the community.
Phase 3 Data Shows TEV-‘749 Injection Improves Social Function in Schizophrenia
Teva presents 2 findings at Psych Congress 2024: TEV’749’s effects on social function and quality of life in adults with schizophrenia and risperidone adherence patterns.
